Roche’s big hope breast cancer drug fails in crucial first-line trial / Endpoints

Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch

DARE Trial: Phase II Study of ctDNA-Guided Intervention in ER+/HER2− Early Breast Cancer — Investigator Perspective

5 hrs / oncodaily

BRCA2-Driven Breast Cancer May Follow A Different Resistance Path On CDK4/6 Inhibitors

16 hrs / oncodaily

Natera Announces Webinar on PALLAS and LEADER Studies in Early Breast Cancer

46 hrs / oncodaily

1 in 3 Americans make financial trade-offs to afford healthcare: Gallup

4 days / beckershospitalreview / Kristin Kuchno

Roche’s big hope breast cancer drug fails in crucial first-line trial

7 days / endpoints / Elizabeth Cairns

Saturday, March 14, 2026, 7:21 pm / permalink 20770 / 5 stories in 47 hrs

Related Stories

Related Tags

Healthcare

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (14 hrs)

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (15 hrs)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (17 hrs)

more #healthcare

Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (15 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (18 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (30 hrs)

more #pharmaceuticals

Biotech

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (15 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (18 hrs)

HORMAD1 emerges as a potential target in triple‑negative breast cancer (43 hrs)

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.